ABSTRACT
Objective: To establish the HPLC fingerprint of Olibanum. Methods: The column was Agilent ZORBAX SBC18(250 mm×4. 6 mm,5 μm) with the mobile phase of acetonitrile-0. 1% phosphoric acid (gradient elution) at a flow rate of 1. 0 ml·min-1, the detection wavelength was 270 nm,the column temperature was 30℃,and the injection volume was 10 μl. Olibanum samples from different regions were detected for the characteristic fingerprint. Similarity evaluation software for chromatographic fingerprint of tradi-tional Chinese medicine (2012 edition) was used for the common peaks identification and similarity evaluation. Results: The HPLC fingerprint analysis method for Olibanum was established. The fingerprint consisted of 10 common peaks. The similarities of the finger-prints of twelve samples from different regions were above 0. 95. Conclusion: The method is simple and rapid with good reproducibili-ty, which provides basis for the quality control and evaluation standard of Olibanum.
ABSTRACT
Objective To investigate the synergistic regulation of KDM3B and JMJD1C in leukemia. Methods The expression level of JMJD1C and KDM3B were analyzed in multiple acute myeloid leukemia (AML) cell lines. AML cell lines NB4 and HL-60 were treated with Daminozide, followed by determination of H3K9 mono-methylation and di-methylation. AML cell lines NB4 and HL-60 were treated with Daminozide, ATRA (retinoid acid All-trans), C Vitamin and the expression of KDM3B and JMJD1C were detected by real-time quantitative PCR. Results The expression level of KDM3B and JMJD1C in the AML cell lines was negatively correlated. In NB4 and HL-60 cells treated by daminozide, H3K9 mono-methylation and di- methylation level showed a rising trend in these two cell groups. After treatment of NB4 cells with the 3 reagents, the level of mRNA of KDM3B was down-regulated while the level of mRNA of JMJD1C was up-regulated. In HL-60 cells treated by daminozide, the mRNA level of KDM3B was up-regulated and the mRNA level of JMJD1C was down-regulated. Conclusion The expression of KDM3B and JMJD1C is negatively correlated in patients with AML.